AbCellera Biologics (ABCL) Debt to Equity (2020 - 2025)
AbCellera Biologics (ABCL) has disclosed Debt to Equity for 6 consecutive years, with $0.01 as the latest value for Q1 2025.
- For the quarter ending Q1 2025, Debt to Equity fell 81.16% year-over-year to $0.01, compared with a TTM value of $0.01 through Mar 2025, down 81.16%, and an annual FY2024 reading of $0.01, down 82.52% over the prior year.
- Debt to Equity was $0.01 for Q1 2025 at AbCellera Biologics, up from $0.01 in the prior quarter.
- Across five years, Debt to Equity topped out at $0.05 in Q2 2023 and bottomed at $0.01 in Q4 2024.
- Average Debt to Equity over 5 years is $0.03, with a median of $0.02 recorded in 2022.
- The sharpest move saw Debt to Equity soared 136.16% in 2022, then plummeted 82.52% in 2024.
- Year by year, Debt to Equity stood at $0.02 in 2021, then skyrocketed by 60.33% to $0.04 in 2022, then increased by 22.19% to $0.04 in 2023, then tumbled by 82.52% to $0.01 in 2024, then increased by 11.97% to $0.01 in 2025.
- Business Quant data shows Debt to Equity for ABCL at $0.01 in Q1 2025, $0.01 in Q4 2024, and $0.02 in Q3 2024.